These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 36812668)
1. Translational implications of humoral and cellular immune dysfunction in granulomatosis with polyangiitis. Singh H; Kumar U; Senapati S Cytokine; 2023 Apr; 164():156154. PubMed ID: 36812668 [TBL] [Abstract][Full Text] [Related]
2. Remission of Granulomatosis with Polyangiitis Only After Resection of a Pulmonary Nodule. Kanda R; Nakano K; Nawata A; Iwata S; Nakayamada S; Tanaka Y Intern Med; 2022; 61(18):2803-2808. PubMed ID: 36104178 [TBL] [Abstract][Full Text] [Related]
3. Serum cytokines in ANCA-associated vasculitis: Correlation with disease-related clinical and laboratory findings. Krajewska Wojciechowska J; Krajewski W; Kościelska-Kasprzak K; Zatoński T Med Clin (Barc); 2021 Nov; 157(10):464-472. PubMed ID: 33097207 [TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of ANCA-associated vasculitis. Lenka B; Zdenka H; Eva H Cesk Patol; 2020; 56(2):65-67. PubMed ID: 32493021 [TBL] [Abstract][Full Text] [Related]
5. Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China. Chang DY; Li ZY; Chen M; Zhao MH Semin Arthritis Rheum; 2019 Feb; 48(4):701-706. PubMed ID: 29887327 [TBL] [Abstract][Full Text] [Related]
6. 4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis. Granel J; Lemoine R; Morello E; Gallais Y; Mariot J; Drapeau M; Musnier A; Poupon A; Pugnière M; Seren S; Nouar D; Gouilleux-Gruart V; Watier H; Korkmaz B; Hoarau C Front Immunol; 2020; 11():573040. PubMed ID: 33101296 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic algorithm for antineutrophil cytoplasmic antibody-associated systemic vasculitis. Beketova TV Ter Arkh; 2018 May; 90(5):13-22. PubMed ID: 30701885 [TBL] [Abstract][Full Text] [Related]
8. Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation. Gibson LE Int J Dermatol; 2022 Dec; 61(12):1442-1451. PubMed ID: 35599359 [TBL] [Abstract][Full Text] [Related]
9. Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies. Granel J; Korkmaz B; Nouar D; Weiss SAI; Jenne DE; Lemoine R; Hoarau C Front Immunol; 2021; 12():571933. PubMed ID: 33679731 [TBL] [Abstract][Full Text] [Related]
10. ANCA-Associated Vasculitis: Core Curriculum 2020. Geetha D; Jefferson JA Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311 [TBL] [Abstract][Full Text] [Related]
11. Granulomatosis with polyangiitis and facial palsy: Literature review and insight in the autoimmune pathogenesis. Iannella G; Greco A; Granata G; Manno A; Pasquariello B; Angeletti D; Didona D; Magliulo G Autoimmun Rev; 2016 Jul; 15(7):621-31. PubMed ID: 26851550 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U; Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483 [TBL] [Abstract][Full Text] [Related]
14. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Lenert A; Lenert P Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919 [TBL] [Abstract][Full Text] [Related]
15. [Recommendations on the diagnosis and treatment of anti-neutrophil cytoplasmic antibody associated vasculitis in China]. Tian XP; Zhao LK; Jiang ZY; Wang Y; Huang CB; Zhao Y Zhonghua Nei Ke Za Zhi; 2022 Oct; 61(10):1128-1135. PubMed ID: 36207967 [TBL] [Abstract][Full Text] [Related]
16. Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management. Trivioli G; Marquez A; Martorana D; Tesi M; Kronbichler A; Lyons PA; Vaglio A Nat Rev Rheumatol; 2022 Oct; 18(10):559-574. PubMed ID: 36109667 [TBL] [Abstract][Full Text] [Related]
17. Environmental factors influencing the risk of ANCA-associated vasculitis. Zhao WM; Wang ZJ; Shi R; Zhu YY; Zhang S; Wang RF; Wang DG Front Immunol; 2022; 13():991256. PubMed ID: 36119110 [TBL] [Abstract][Full Text] [Related]
18. Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Deshayes S; Martin Silva N; Khoy K; Yameogo S; Mariotte D; Lobbedez T; Aouba A Rheumatology (Oxford); 2019 Oct; 58(10):1731-1739. PubMed ID: 30805643 [TBL] [Abstract][Full Text] [Related]
19. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nakazawa D; Masuda S; Tomaru U; Ishizu A Nat Rev Rheumatol; 2019 Feb; 15(2):91-101. PubMed ID: 30542206 [TBL] [Abstract][Full Text] [Related]